hVIVO (OPORF) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


OPORF hVIVO PLC OPORF
43 GF Score
Price $0.11
GF Value $0.60
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is hVIVO Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

hVIVO's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

OPORF vs TMO, DHR, IDXX: Margin of Safety % (DCF Earnings Based) Comparison

For the Diagnostics & Research subindustry, hVIVO's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

hVIVO Margin of Safety % (DCF Earnings Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, hVIVO's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where hVIVO's Margin of Safety % (DCF Earnings Based) falls into.


OPORF
43GF Score
hVIVO PLC OPORF
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is hVIVO (OPORF) Overvalued in 2026?

Based on GuruFocus' analysis, hVIVO stock appears to be undervalued. The current stock price of $0.11 is trading 81.7% below its estimated GF Value™ of $0.60. GuruFocus considers hVIVO to be Possible Value Trap.

Key valuation signals for OPORF:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.60 vs. price of $0.11 (81.7% below fair value)
  • GF Score™: 43/100 with 6 warning signs

No single metric tells the full story. See the OPORF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

hVIVO Business Description

Other Exchanges HVO:UKCRO:Germany
Address 40 Bank Street, Floor 24, London, GBR, E14 5NR
hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.
43GF Score

Get the complete analysis for OPORF

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.11
Price
$0.60
GF Value